Obermatt
See Similar Stocks →

Flags

Financial distress

Exact Sciences

NAQ:EXAS · US30063P1057
BiotechnologyLarge

360

20
Medium confidence — indicative
Profit price100
Owner Earnings Yield1
Dividend Yield1
Price/Sales71
EV / Gross Profit61
Price/Book15
Return on Capital56
Cash Return on Capital53
Return on Equity51
EBIT Margin43
Gross Profitability78
Accruals77
Owner Earnings Margin50
Sales growth60
Profit growth3
Reinvestment81
Price momentum78
Debt load10
Refinancing81
Debt Payback1
Liquidity84
Analyst ratings3
Expectations trend2
Market mood29
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Exact Sciences doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeLarge
TypePrivate Company
ExchangeNASDAQGM
Founded1995
Employees5,322
Websiteexactsciences.com
ISINUS30063P1057
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)D.J. US Health Care
Themes
GeneticsHealth DiagnosticsOncologyBiotechnology

Description

Exact Sciences Corporation provides cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. The company is investing in its pipeline to develop innova…

Analysis

Middle-of-the-road

Exact Sciences Corporation is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is mixed and the balance sheet is fragile. The company scores 4/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

What to watch: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
36
2026

All-time high

53

Feb 2026

All-time low

36

Mar 2026

Average rank

45

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
71
—
—
—
Price/Earnings
1
—
—
—
Price/Book
15
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
20
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Exact Sciences with its peers
Benitec Biopharma
NAQ:BNTC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Pacific Biosciences of California
NSQ:PACB
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Beam Therapeutics
NSQ:BEAM
17
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Greenwich Lifesciences
NAQ:GLSI
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Legend Biotech
NSQ:LEGN
30
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Tango Therapeutics
NMQ:TNGX
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →